On December 5, 2023, the Innovation and Value Initiative (IVI), the Alliance for Aging Research, National Pharmaceutical Council, and Leavitt Partners, LLC, hosted a half-day symposium to examine issues related to equity and patient engagement in implementation of the Inflation Reduction Act of 2022 (IRA) by the Centers for Medicare & Medicaid Services (CMS). [...]
In celebration or Rare Disease Awareness Month, the video "Bridging the Gap, Empowering Patients: A Collaborative Approach to Rare Disease Research" highlights the significance of adopting a collaborative, patient-centered approach in rare disease research. Led by the Innovation and Value Initiative and Alexion, AstraZeneca Rare Disease, the conversation underscores the importance of transforming the [...]
The Innovation and Value Initiative (IVI) is pleased to announce the completion of its 4th Annual Meeting, our second in-person meeting since the pandemic. We were thrilled to see our esteemed members, partners, and colleagues participate in many important discussions. This year, we featured multiple IVI research initiatives, including the IVI Major Depressive Disorder (IVI-MDD) [...]
Alexandria, VA – August 29, 2023 – The Innovation and Value Initiative (IVI), a non-profit research organization committed to advancing the science, practice, and use of health technology assessment in health care, today issued a statement in response to the Centers for Medicare and Medicaid Services’ (CMS) announcement of the first prescription drugs selected for price negotiations under the [...]
By Jason Spangler, MD, MPH, FACPM (CEO, Innovation and Value Initiative) In March, the Centers for Medicare and Medicaid Services (CMS) released draft guidance for its implementation of the Drug Price Negotiation Program (DPNP), a key component of the Inflation Reduction Act (IRA). This release and its associated comment period sparked far-ranging debate and [...]
IVI submitted comments on the ICER 2023 Value Assessment Framework. We appreciate the opportunity to provide comments on this important issue. In revising its value assessment framework, IVI recommends that ICER make modifications related to proposed methodological changes, patient engagement strategies, and methods for handling data gaps to increase equity within health technology assessment. [...]
It is with mixed emotions we announce that Jennifer Bright, MPA, will be stepping down from her position as Chief Strategy and Engagement Officer effective June 30th. Ms. Bright joined IVI in 2017 and served as the organization's first Executive Director and then Chief Executive Officer until July 2022, when she transitioned into her [...]
IVI, in partnership with AcademyHealth, released a joint report, “A Research Framework to Understand the Full Range of Economic Impacts on Patients and Caregivers,” for researchers, value assessors, and other decision-makers to address the full range of economic impacts on patients. This report was made possible through funding support from the Eugene Washington PCORI [...]
IVI submitted comments on the Centers for Medicare and Medicaid Services' (CMS) initial guidance for the implementation of the Medicare Drug Price Negotiation Program (Medicare DPNP). We appreciate the opportunity to provide comment on this important issue. Read our full comments here. ### About IVI The Innovation and Value Initiative (IVI) is a [...]
IVI is pleased to share our recently published manuscript, co-authored with the RAND Corporation, in the Journal of Comparative Effectiveness Research. For this manuscript, IVI collaborated with a steering committee and surveyed patients with rheumatoid arthritis (RA) to discover a new method for engaging patients in healthcare valuation using patient-specific goals. The findings indicated [...]
